Morgan Stanley Downgrades Axsome Therapeutics to Equal-Weight, Raises Price Target to $204

Benzinga · 3d ago
Morgan Stanley analyst Sean Laaman downgrades Axsome Therapeutics (NASDAQ:AXSM) from Overweight to Equal-Weight and raises the price target from $196 to $204.